KINGWORLD MEDICINES GROUP LIMITED
金活醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 01110)

ESTIMATE FOR INTERIM RESULTS OF 2025

This announcement is made by Kingworld Medicines Group Limited (the "**Company**" and together with its subsidiaries, the "**Group**") pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 (the "**Period**") and the information currently available to the Board, the Group is expected to record a decrease in profit of the Group by approximately 70% to 75% for the Period as compared to the profit of approximately RMB45.6 million for the six months ended 30 June 2024 (the "**Previous Period**").

The Board considers that the decrease in the profit of the Group was mainly due to a decrease in the gross profit from distribution of imported branded pharmaceutical and healthcare products in China by approximately 50% to 55%, primary due to a slowdown in the demand of the related products in the market. Such decrease was partially offset by the increase in gross profit from Shenzhen Dong Di Xin Technology Company Limited* (深圳市東迪欣科技有限公司) ("**Dong Di Xin**") by approximately 10% to 15%.

Dong Di Xin, the Company's non-wholly owned subsidiary, is a medical devices manufacturer that produces various medical devices including infrared thermometers, electrophysical therapy and rehabilitation equipment.

As a result of the above, the Group is expected to record a loss attributable to owners of the Company of approximately RMB4.5 million for the Period as compared to the profit attributable to owners of the Company of approximately RMB30.7 million for the Previous Period.

Information contained in this announcement is based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the Period and information currently available to the Board. Information in this announcement has not been reviewed nor audited by the auditors of the Company, nor reviewed by the audit committee of the Company. The actual results of the Group for the Period are subject to adjustment and may differ from the information disclosed herein. Shareholders and potential investors are advised to read carefully the results announcement of the Group for the Period, which is expected to be published by the Company on 27 August 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Kingworld Medicines Group Limited
Zhao Li Sheng
Chairman

Hong Kong, 21 August 2025

As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San and Mr. Zhou Xuhua, the independent non-executive Directors are Mr. Duan Jidong, Mr. Wong Cheuk Lam and Dr. Chu Xiaoping.

* *For identification purpose only*